HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Consumer Health Fraud: Collidial Silver A Pandemic Repeat Offender

Executive Summary

COVID-19 makes silver a gift that keeps on giving for US regulators with another business closed by court order; Seattle area naturopath charged with selling misbranded drug as a virus prevention; FTC reaches settlements with operators of “free trial” schemes for cosmetics and supplements; FDA announces criminal convictions of two men who defrauded the agency by misbranding steroid drugs they sold OTC.

You may also be interested in...



Children's Use Of New Earth Healing's Colloidal Silver Eye Drops, Nasal Sprays Concerns US FDA

Children, a vulnerable population, are particularly at risk of "unpredictable and unintended consequences" from untested drug products, FDA warns colloidal silver marketer.

US 2021 Consumer Health Fraud Headaches Include Securities Scam By ‘Fast-Acting Aspirin’ Firm

FDA worked on investigations with US Attorneys’ offices and other federal agencies of unlawful sales of supplements promoted to prevent or treat COVID-19 as well as other diseases and health conditions and of prescription drugs offered OTC for muscle growth or sexual enhancement.

Criminal Charges, Warnings Continue Climbing In US COVID-19 Consumer Health Fraud Enforcement

FDA counts 102 warning letters covering more than 1,000 products in its coronavirus fraud oversight while FTC’s  total had reached 332. Latest criminal charges are against operator of a Georgia business following FDA investigation of OTC sales of a misbranded drug called “Immune Shot” falsely advertised to lower consumer’s risk of contracting COVID-19 by nearly 50%.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel